Parkview Health

Group 3 Pulmonary Hypertension: Mechanistic Insights, Clinical Challenges, and Evolving Therapies

Group 3 pulmonary hypertension is a common and clinically significant complication of chronic lung disease and hypoxia that is associated with impaired functional capacity, right ventricular dysfunction, and increased mortality. Historically viewed as a consequence of underlying...

Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer

Abstract Daraxonrasib is an orally bioavailable RAS(ON) multi-selective tri-complex inhibitor of the oncogenic mutant and wild-type variants of N, H and KRAS. We previously reported encouraging efficacy in a phase 1/2 clinical trial evaluating daraxonrasib monotherapy at clinical...